Immune signature-based hepatocellular carcinoma subtypes may provide novel insights into therapy and prognosis predictions

BACKGROUND: Hepatocellular carcinoma (HCC) has a poor prognosis and has become the sixth most common malignancy worldwide due to its high incidence. Advanced approaches to therapy, including immunotherapeutic strategies, have played crucial roles in decreasing recurrence rates and improving clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Qiuxian, Yang, Qin, Zhou, Jiaming, Gu, Xinyu, Zhou, Haibo, Dong, Xuejun, Zhu, Haihong, Chen, Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243542/
https://www.ncbi.nlm.nih.gov/pubmed/34193146
http://dx.doi.org/10.1186/s12935-021-02033-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243542/
https://www.ncbi.nlm.nih.gov/pubmed/34193146
http://dx.doi.org/10.1186/s12935-021-02033-4

Ejemplares similares